'Novo Nordisk now has more than 45,000 people in ongoing or planned trials for semaglutide, the active ingredient in the blockbuster drugs, and CagriSema, a next-generation version of the treatment that combines semaglutide with another compound, a Financial Times analysis of clinical trial data shows.'

https://www.ft.com/content/2ea93480-f6dc-4714-aeaa-036427eafe53